CLOZAPINE TABLETS
Krajina: Kanada
Jazyk: angličtina
Zdroj: Health Canada
Súhrn charakteristických
(SPC)
11-10-2018
Niektoré dokumenty týkajúce sa tohto produktu nie sú momentálne k dispozícii, môžete poslať požiadavku na náš zákaznícky servis a my vás upozorníme hneď, ako ich dokážeme získať.
Poslať žiadosť.
Poslať žiadosť.
Aktívna zložka:
CLOZAPINE
Dostupné z:
INNOMAR STRATEGIES INC.
ATC kód:
N05AH02
INN (Medzinárodný Name):
CLOZAPINE
Dávkovanie:
100MG
Forma lieku:
TABLET
Zloženie:
CLOZAPINE 100MG
Spôsob podávania:
ORAL
Počet v balení:
100
Typ predpisu:
Prescription
Terapeutické oblasti:
ATYPICAL ANTIPSYCHOTICS
Prehľad produktov:
Active ingredient group (AIG) number: 0122583002; AHFS:
Stav Autorizácia:
APPROVED
Dátum Autorizácia:
2018-10-11
Súhrn charakteristických
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
Clozapine Tablets
25 mg and 100 mg
House Standard
Antipsychotic Agent
Innomar Strategies Inc. DATE OF REVISION:
3470 Superior Court October 11, 2018
Oakville, Ontario
L6L 0C4
Control No.: 219938
_Product Monograph _
_August 2018 _
_Page 2 of 57_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................... 3
SUMMARY PRODUCT INFORMATION
.........................................................................
3
INDICATIONS AND CLINICAL USE
...............................................................................
3
CONTRAINDICATIONS
..................................................................................................
5
WARNINGS AND PRECAUTIONS
.................................................................................
5
ADVERSE REACTIONS
...............................................................................................
21
DRUG INTERACTIONS
................................................................................................
28
DOSAGE AND ADMINISTRATION
...............................................................................
29
OVERDOSAGE
............................................................................................................
33
ACTION AND CLINICAL PHARMACOLOGY
................................................................ 35
STORAGE AND STABILITY
.........................................................................................
36
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................... 36
PART II: SCIENTIFIC INFORMATION
....................................................................................
38
PHARMACEUTICAL INFORMATION
...........................................................................
38
CLINICAL TRIALS
........................................................................................................
39
DETAILED PHARMACOLOGY
...........................
Prečítajte si celý dokument
